Thalassemia Treatment Market Research Report - Global Forecast till 2032

Thalassemia Treatment Market Research Report Information by Type (Alpha-thalassemia, Beta Thalassemia), Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplants), End User (Hospitals and Clinics, Diagnostic Laboratories and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2032

ID: MRFR/HC/7123-HCR | 90 Pages | Author: Kinjoll Dey | March 2024         

Thalassemia Treatment Market Speak to Analyst Request a Free Sample

Thalassemia Treatment Market Outlook


The Thalassemia Treatment Market is projected to reach USD 15.1 Billion by 2032 at 10.7% CAGR during the forecast period 2023-2032. Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.


Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.


Thalassemia Treatment Market Influencers


Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the Thalassemia Treatment Market.


Market Drivers



  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.



  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.



  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the Thalassemia Treatment Market.



  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.


Market Restraints



  • Stringent regulatory policies

  • High treatment costs


Thalassemia Treatment Market Segmentation


By Type



  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.



  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.


By Treatment



  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.



  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.



  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.



  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.



  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the Thalassemia Treatment Market growth in this segment.


By End-User



  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.



  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.



  • Others: This segment includes research laboratories, educational institutes, among others.


By Region



  • Americas: The largest growing regional Thalassemia Treatment Market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.



  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.



  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.



  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.


Thalassemia Treatment Market Key Players



  • Novartis AG (Switzerland)

  • Bluebird Bio, Inc. (US)

  • Kiadis Pharma (Netherlands)

  • CELGENE CORPORATION (US)

  • Sangamo Therapeutics (US)

  • Acceleron Pharma, Inc. (US)

  • Gamida Cell (Israel)

Report Scope:

Report Attribute/Metric Details
聽聽Market Size 聽聽USD 15.1 Billion
聽聽CAGR 聽聽10.7%
聽聽Base Year 聽聽2019
聽聽Forecast Period 聽聽2032
聽聽Historical Data 聽聽2018
聽聽Forecast Units 聽聽Value (USD Million)
聽聽Report Coverage 聽聽Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
聽聽Segments Covered 聽聽Type, Treatment, End-User and Region
聽聽Geographies Covered 聽聽North America, Europe, Asia-Pacific, and Rest of the World (RoW)
聽聽Key Vendors 聽聽Novartis AG (Switzerland), Bluebird Bio, Inc. (US), Kiadis Pharma (Netherlands), CELGENE CORPORATION (US), Sangamo Therapeutics (US), Acceleron Pharma, Inc. (US), Gamida Cell (Israel)
聽聽Key Market Opportunities 路聽 Mergers and acquisitions 路聽 New product developments 路聽 Regional expansions
聽聽Key Market Drivers 路聽 Increasing pipeline drugs 路聽 Demand for gene therapy 路聽 Awareness regarding available treatment




Frequently Asked Questions (FAQ) :

Global Thalassemia Treatment Market is projected to grow at approximately 10.7% CAGR during the assessment period (2023-2032).

Global Thalassemia Treatment Market is estimated to reach a valuation of approx. USD 15.1 Billion by the end of 2032

Rising thalassemia diagnosed cases, increasing pipeline drugs and awareness about the condition & available treatment options, are major tailwinds pushing the growth of the Global Thalassemia Treatment Market.

North America holds the largest share in the Global Thalassemia Treatment Market, followed by Europe and the Asia Pacific, respectively.

Novartis AG (Switzerland), Bluebird Bio, Inc. (US), Kiadis Pharma (Netherlands), Celgene Corporation (US), Sangamo Therapeutics (US), Acceleron Pharma, Inc. (US), and Gamida Cell (Israel), are some of the top players operating in the Global Thalassemia Treatment Market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players鈥 financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid